Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients
|
|
- Nigel Heath
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2006) 21: doi: /ndt/gfi086 Advance Access publication 6 September 2005 Original Article Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients Helmut Schiffl 1,2 and Susanne M. Lang 2 1 KfH Nierenzentrum Mu nchen-laim, Munich, Germany and 2 Department of Internal Medicine, University of Munich, Munich, Germany Abstract Background. While folic acid deficiency causes macrocytic anaemia in non-renal patients, the relevance of altered folate metabolism in anaemia of end-stage renal disease and its response to rhu-epo is less clear. Methods. Ten haemodialysis patients with macrocytic anaemia due to dietary folic acid deficiency were compared to 10 matched (age, duration of dialysis, degree of anaemia) patients with normocytic normochromic anaemia. Ninteen patients received erythropoietin-alpha intravenously thrice weekly. The study design was a prospective crossover (ABA) comparison of the effects of intravenously administered high doses of folic acid on haemoglobin levels and EPO doses, with 6 months active supplementation (B) and two periods of 6 months duration each without folic acid supplementation (A). Results. The two patient groups did not differ at recruitment. Red blood cell folate levels were normal in patients with normocytic anaemia, but they were subnormal in all patients with macrocytic anaemia. Compared to the first period without folic acid supplementation, patients with macrocytic anaemia had significantly higher haemoglobin levels despite lower EPO doses after 6 months high-dose folic acid, and red cells had become normocytic. The removal of folic acid supplementation resulted in re-occurrence of macrocytosis and in a significantly lower response to rhu-epo. In contrast, high-dose folic acid supplementation had no effect on response to rhu-epo in patients with normocytic anaemia. Conclusions. Folic acid deficiency may occur in elderly haemodialysis patients with poor dietary folate intake without regular oral supplementation and may cause hyporesponsiveness to rhu-epo. Macrocytosis is a simple and cheap indicator for folate deficiency in Correspondence and offprint requests to: H. Schiffl, KfH Nierenzentrum Mu nchen Laim, Elsenheimerstr. 63, D80687 Munich, Germany. hschiffl@hotmail.com end-stage renal disease patients on maintenance dialysis. Keywords: folic acid deficiency; macrocytic anaemia; maintenance haemodialysis; rhu-epo Introduction Normocytic normochromic anaemia is a virtually universal feature among patients with end-stage renal disease (ESRD) on maintenance dialysis. While the primacy of insufficient production of erythropoietin by the diseased kidneys is indisputable, the haematopoietic response to rhu-epo may be affected by various factors related either to uraemia or its treatment. There is ample evidence that iron deficiency, inflammation/infection, hyperparathyroidism or aluminium intoxication may contribute to the severity of renal anaemia and hence increase recombinant human erythropoietin requirements. There is also no doubt that patients with ESRD may develop any of the common causes of anaemia [1]. Folate deficiency has been implicated as a modulating factor in renal anaemia and as a cause of hypo-responsiveness to erythropoietin treatment [2]. However, despite loss of folate into the dialysate [3] and increased folate requirements during rhu-epo treatment [4] relevant folate deficiency is unlikely to occur in well-nourished dialysis patients [5,6]. Furthermore, supplementation of folic acid did not appear to have a beneficial effect on erythropoiesis or on erythropoietin response when serum folate levels were within the normal range [7,8]. Therefore, routine supplementation of folate is not recommended in patients on regular haemodialysis as adjuvant therapy of renal anaemia [9]. The present investigation aimed to identify folic acid deficiency by macrocytic anaemia in an outpatient ß The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 134 H. Schiffl and S. M. Lang dialysis population and to characterize the response of combined renal and folic acid deficiency anaemia to rhu-epo therapy in a small group of patients. Subjects and methods Subjects Ten patients (4 men, 6 women, aged years) with macrocytic anaemia were identified from an outpatient population of 136 patients maintained on regular dialysis therapy. None of these patients had symptoms of malabsorption or known gastrointestinal disorders, a myeloproliferative syndrome, viral infection or liver disease. No patient was taking drugs known to cause megaloblastic anaemia or was a heavy alcoholic. None of the female patients was pregnant. They all had serum cobalamin, LDH, liver enzymes and bilirubin levels within the normal range. None of the patients had glossitis, neurological or psychiatric symptoms. Nine patients received erythropoietin alpha (Erypo, Ortho Biotec; Cilag Janssen, Neuss, Germany) intravenously thrice weekly at the end of a haemodialysis session. One more patient had macrocytic anaemia with haemoglobin levels consistently over 11 g/dl and was not treated with rhu-epo. The study patients were matched with 10 dialysis patients with normocytic normochromic anaemia. Matching criteria were age, duration of dialysis and degree of anaemia. The 10 control patients received erythropoietin alpha (Erypo, Ortho Biotec, Cilag Janssen, Neuss, Germany) intravenously thrice weekly after haemodialysis for partial correction of their renal anaemia. None of the 20 dialysis patients had iron deficiency judged by determinations of serum iron, ferritin and transferrin, infection (by CRP levels), severe hyperparathyroidism (by intact PTH concentrations), excess aluminium levels or occult blood loss (haemoccult testing). Oral medications included antihypertensive drugs (beta blockers, angiotensin-converting enzyme inhibitors, calcium antagonists in six patients of each group), calcium acetate, aluminium hydroxide and sevelamer. To replete iron stores ferrum(iii) sodium gluconate (Ferrlecit, Aventis, Frankfurt a. Main, Germany) was given intravenously according to the individual patient s needs to maintain serum ferritin levels between 300 to 500 ng/ml and transferrin saturation values at 20 to 40%. To avoid iron overload (i.e. serum ferritin over 800 ng/ml and/or transferrin saturation over 50%) maintenance intravenous iron therapy was withheld and restarted with a reduced dose (50%) when serum ferritin levels fell below 800 ng/ml. Haemodialysis Haemodialysis was performed thrice weekly for 4 5 h, using machines with volumetrically controlled ultrafiltration (MTS 4008, FMC, Bad Homburg v.d.h., Germany), new synthetic high-flux membranes (APS 650, polysulfone, Asahi Medical Co, Tokyo, Japan) and ultrapure bicarbonate-based dialysate (by additional one step online filtration). for the study gave written consent. In Germany, folic acid preparations are classified as dietary supplements and not as drugs and are available without prescription. The laboratory monitoring tests were either routinely performed in the haemodialysis unit or recommended for evaluation of anaemia or responsiveness of rhu-epo. There were no additional samples drawn for study purposes. The investigations were performed as an unblinded prospective cross-over comparison (ABA-sequence) of the effects of intravenously administered high-dose folic acid (folic acid, Hevert Arzneimittel, Nußbaum, Germany). The study protocol included three phases of 6 months duration each: an observation phase without intravenous folic acid supplementation (A), a second phase (B) with high-dose folic acid supplementation (20 mg thrice weekly at the end of a dialysis session), and a final phase without supplementation (A). Folic acid was administered intravenously to guarantee compliance and to avoid differences in bioavailability. Laboratory investigations Blood specimens from each patient were collected at recruitment and at the end of each study period into lightprotected tubes. Serum and whole blood aliquots were frozen immediately and stored at 20 C until analysis. Serum folate, erythrocyte folate and serum vitamin B12 were quantified by an automated chemiluminescence microparticle immunoassay on the Architect system (Abbott Diagnostics, Abbott Park, Illinois, USA). Conditions specified by the manufacturer were used to prepare whole blood haemolysate [10]. Complete blood cell count, iron indices, intact parathyroid hormone and serum aluminium were measured by routine methods at recruitment. Blood cell counts were repeated every 6 weeks, iron indices were evaluated every 12 weeks, Kt/V urea was calculated every 6 months. Reference values for serum folic acid were ng/ml, for whole blood folate ng/ml and for serum vitamin B12 levels pg/ml. The Architect folate assay and Architect B12 assay precision (total coefficient of variation in percent) was below 7% for low and normal serum folate levels, for low or normal erythrocyte folate concentrations and for normal vitamin B12 concentrations. The normal range for the mean corpuscular volume of erythrocytes was 83 to 95 fl, macrocytosis was defined by MCV values greater than 96 fl. Dietary record A 7 day dietary record assessed nutrient intakes of the study patients at recruitment and after each of the three study periods. Folate values were calculated with the FOODOPT software, which is based on the German Food Code and Nutrient Database. The calculated folate intake was compared with the corresponding recommended dietary allowance for the particular age and sex. The current German recommendation for both men and women is 400 mg folate per day. This amount is based on the folate content for raw materials [11]. Study design The study was conducted according to the Declaration of Helsinki and the ICH GCP guidelines. All patients enrolled rhu-epo dosage Target haemoglobin concentrations in patients receiving rhu-epo were 11 to 12 g/dl. rhu-epo dosages were
3 Folic deficiency and haematopoietic response 135 adjusted by a 25% reduction or 25% augmentation to the closest 1000 units if haemoglobin levels rose above 13 g/dl or fell below 10 g/dl. Dose adjustments were made on a caseby-case basis at each assessment time point by the attending nephrologists, who were not necessarily identical with the study physicians. Table 1. Characteristics of patients with macrocytic anaemia (MCV fl) and normocytic anaemia (MCV fl) at recruitment. Macrocytic anaemia Normocytic anaemia Statistics Data are presented as mean±sd. The Mann Whitney U-test was applied to study differences between the two groups and the Wilcoxon rank test was used for the paired differences within the groups. A P-value of less than 0.05 was considered to reflect statistical differences. Results Characteristics at recruitment The two patient groups were comparable regarding mean age, distribution of gender, causes of end-stage renal disease, body mass index and time on haemodialysis. All patients were adequately dialyzed. They had similar mean PTH levels, none of the patients had excess hyperaluminaemia. The number of patients taking angiotensin-converting enzyme inhibitors was identical. All patients were iron-repleted, none of the patients had biochemical evidence of infection/ inflammation. Serum folate and vitamin B12 levels were above the lower values of the normal range in each patient and the mean concentration of the two vitamins did not differ among groups. All patients with macrocytic anaemia had red cell folate levels below the cut-off. Normocytic anaemia was associated with normal red cell folate levels in all cases. Pre-dialysis haemoglobin levels did not differ between groups, but there was a need for higher rhu-epo doses in macrocytic patients (Table 1). Dose of rhu-epo and folic acid supplementation All 20 patients completed the three study periods. High-dose folic acid was well-tolerated by all participants, folic acid deficiency was not associated with clinical signs other than macrocytic anaemia. During the first period, patients with macrocytic or with normocytic anaemia exhibited no significant changes in haemoglobin concentrations or erythrocyte cell volume. There was a need for higher doses of rhu-epo (units per week related to patients body weight) in patients with macrocytic anaemia during the first 6 months of the study. In the second period, intravenous supplementation with high-dose folic acid was well-tolerated by all patients and resulted in supra-physiologic serum folate concentrations. Supplementation with high doses of folic acid caused a normalization of the erythrocyte cell volume and a significant reduction in rhu-epo dose (to reach similar target haemoglobin concentrations) in the nine patients with macrocytic anaemia Number of patients Age (years) 56 (9) 54 (12) Gender (m/f) 4/6 5/5 Time on HD (months) 62 (14) 56 (12) Body mass index (kg/m 2 ) 23 (5) 23 (2) Kt/V urea 1.3 (0.1) 1.2 (0.1) ipth (pg/ml) 101 (33) 88 (22) Ferritin (ng/ml) 544 (82) 602 (104) Transferrin saturation (%) 27 (3) 29 (4) Serum folate(ng/ml) 12 (4) 10 (5) Red blood cell folate (ng/ml) 122 (17) 480 (144)* Serum vitamin B12 (pg/ml) 622 (144) 580 (192) CRP (mg/dl) 0.3 (0.2) 0.2 (0.1) ACE-Inhibitors (patients/n) 3/10 3/10 MCV (fl) 106 (3) 88 (3) Haemoglobin (g/dl) 10.9 (0.2) 11.0 (0.2) rhu-epo dose (IU/kg/week) 79 (12) 48 (9) Data are given as mean (±SD). *P ¼ 0.05 vs corresponding value. A B A A B A Macrocytic anaemia Normocytic anaemia Fig. 1. Haemoglobin levels in patients with macrocytic or normocytic anaemia at the end of the three study periods. Data are given as mean±sd. *P<0.05 vs pre-treatment value. receiving rhu-epo. By contrast, in normocytic patients neither the response of anaemia to rhu-epo nor erythrocyte cell volume was changed by high-dose folic acid (Figures 1 and 2 and Table 2). During the last 6 months of the study without intravenous administration of folic acid, there was a re-occurrence of macrocytosis and an increase in rhu-epo requirements in the nine previously macrocytic anaemic patients, but no significant changes were observed in the patient group with normocytic anaemia (Figures 1 and 2 and Table 2). In the patient with macrocytic anaemia who was not on rhu-epo, high doses of folic acid induced a sustained increase in the haemoglobin level from 11.2 to 13.4 g/dl and a reduction in MCV from 103 fl to 93 fl.
4 136 H. Schiffl and S. M. Lang rhu-epo dose (IU/kg/week) Withdrawal of intravenous folic acid supplementation resulted in the re-occurrence of macrocytic anaemia in the non-rhu-treated patient (Hb 10 g/dl, MCV 103 fl). Discussion * A B A A B A Macrocytic anaemia Normocytic anaemia Fig. 2. rhu-epo doses in patients with macrocytic or normocytic anaemia at the end of the three study periods. Data are given as mean±sd. *P<0.05 vs pre-treatment value. Table 2. Iron status indices, erythrocyte corpuscular volume and red blood cell folate concentration at the end of the three study periods (mean±sd) Ferritin (ng/ml) TSAT (%) MCV (ml) RBC folate (ng/ml) Macrocytic anaemia (n ¼ 9) No folic acid (A) 578 (62) 29 (2) 104 (2) 104 (12) Folic acid suppl. (B) 520 (54) 31 (3) 94 (4)* Above normal range No folic acid (A) 596 (72) 27 (2) 106 (2) 125 (14) Normocytic anaemia (n ¼ 10) No folic acid (A) 610 (48) 31 (3) 89 (3) 642 (122) Folic acid suppl. (B) 570 (66) 30 (4) 90 (2) Above normal range No folic acid (A) 535 (53) 28 (2) 88 (4) 680 (140) TSAT, transferrin saturation. *P ¼ 0.05 vs corresponding value. The major results of the present investigation demonstrate that folate deficiency with subsequent folateinduced megaloblastosis impairs the haematopoietic response to erythropoietin in a small group of patients with renal anaemia undergoing maintenance haemodialysis. The numeric estimate of the incidence of folate deficiency in patients with end-stage renal disease treated with non-transplant renal replacement techniques has not been determined. Current routine folate supplementation for haemodialysis patients with lowdose folic acid (1 2 mg/day) or treatment of hyperhomocysteinaemia in this patient population with high-dose folic acid (5 15 mg/day) may have resulted in a low incidence of this form of vitamin deficiency [9]. From our 136 outpatient haemodialysis population, 10 patients presented with megaloblastic anaemia and showed intracellular folate deficiency, as evidenced by low RBC levels. The utility of red cell indices, particularly of the classical parameter mean cell volume or red blood cell distribution width as indicators for folate deficiency was studied by Fialon et al. [12] in regular dialysis patients treated with rhu-epo. These authors conclude that red blood cell parameters may be an inexpensive sensitive test to detect vitamin B12 or folate deficiency in iron-repleted haemodialysis patients. Assessment of folate status should include serum folate and RBC folate levels [13]. Serum folate may be the earliest indicator of folate deficiency, but does not reflect folate body stores. While serum folate levels respond quickly to changes in diet and low folate levels may reflect low dietary intake during the previous 2 3 days, RBC folate levels do not fluctuate with changes in diet during the lifespan of the erythrocytes. RBC folate levels are usually low in patients with folate deficiency. The incidence of folate deficiency in CAPD patients or haemodialysis patients is dramatically overestimated by using common cut-off values of normal serum folate concentrations [14]. Bamonti-Catena and co-workers found low serum folate levels in 63% of their patients, but more than 80% of these patients had RBC folate concentrations within the normal range [15]. In our elderly (8 of 10 were aged 60 years and more) patients, folate deficiency was caused by low dietary intake as in the majority of cases in the general population. Major dietary sources of folic acid are enriched bread and grains, fortified cereals, raw cruciferous or green leafy vegetables or citrus fruits (oranges). The dietary record demonstrated that all our patients with macrocytic anaemia failed to achieve the recommended daily folate intake of 400 mg/day. None of the patients took oral vitamin supplements. In Germany, cereals, with few exceptions, are not enriched with folate. Moreover, our patients cooked foods in water with excessive heat and destroyed the folic acid to some extent. Poor dietary intake may be aggravated by loss of appetite in an elderly patient with end-stage renal disease. Folate may also be lost during the dialysis process, particularly with high-flux haemodialysis [3]. Resistance to erythropoietin therapy remains an important problem in the treatment of anaemia in patients with end-stage renal disease. High intravenous folate supplementation corrected the haematological features of folate deficiency. There was a fall in MCV back to the normal range, and a rise in haemoglobin allowing reduction of rhu-epo to reach target concentrations. These observations are in line with the anecdotal observation that correction of vitamin B12 and folate deficiency improved the responsiveness to erythropoietin in a patient who developed macrocytic anaemia during rhu-epo therapy [16]. Furthermore, Pronai et al. reported that folic acid supplementation
5 Folic deficiency and haematopoietic response 137 improved erythropoietin response and normalized mean corpuscular erythrocyte volume in 11 patients with chronic renal failure receiving either conservative treatment or maintenance dialysis [17]. Despite normal serum folate and vitamin B12 levels, these patients had developed macrocytosis and partial resistance to rhu-epo. Unfortunately, the authors did not measure RBC folate concentrations. In contrast we and others [7,8,18,19] found no improved erythropoietin response even after high-dose folic acid administration to dialysis patients with normocytic or elevated MCV but normal red cell folate concentrations. Folate deficiency may occur in elderly nonsupplemented end-stage renal disease patients maintained on dialytic therapy with poor dietary intake of food not enriched with folate or water cooked food. Vitamin B12 and red blood cell folate levels should be assayed in all cases showing megaloblastic anaemia, as correction of dietary folate deficiency by oral supplementation is simple, effective and will improve the responsiveness to erythropoietin in such patients. There is a need for further investigations to characterize the incidence of folic acid deficiency in maintenance dialysis patients and the optimal route and dose of folic acid supplementation in patients with poor dietary folic acid intake. Acknowledgements. The study was supported in part by a grant from OrthoBiotech. Conflict of interest statement. None declared. References 1. Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP. Megaloblastic hematopoiesis in uremia and in patients on longterm hemodialysis. N Engl J Med 1967; 276: Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16 [Suppl 7]: Leblanc M, Pichette V, Geadah D, Ouimet D. Folic acid and pyridoxal-5 0 -phosphate losses during high-efficiency hemodialysis in patients without hydrosoluble vitamin supplementation. J Ren Nutr 2000; 10: Duclos J, Sieberth HG, Mann H. [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?]. Rev Med Chil 1993; 121: Fodinger M, Veitl M, Skoupy S et al. Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. Kidney Int 2003; 64: Tamura T, Johnston KE, Bergman SM. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol 1996; 7: Ono K, Hisasue Y. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Clin Nephrol 1992; 38: Westhuyzen J, Matherson K, Tracey R, Fleming SJ. Effect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 1993; 40: Teschner M, Kosch M, Schaefer RM. Folate metabolism in renal failure. Nephrol Dial Transplant 2002; 17 [Suppl. 5]: Owen WE, Roberts WL. Comparison of five automated serum and whole blood folate assays. Am J Clin Pathol 2003; 120: Wolters M, Hermann S, Hahn A. B vitamin status and concentrations of homocysteine and methylmalonic acid in elderly German women. Am J Clin Nutr 2003; 78: Fialon P, Leaute AG, Sassier P, Vallot C, Wone C. Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin. Pathol Biol (Paris) 1993; 41: Galloway M, Rushworth L. Red cell or serum folate? Results from the National Pathology Alliance benchmarking review. J Clin Pathol 2003; 56: De Vecchi AF, Bamonti-Catena F, Finazzi S et al. Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int 2000; 20: Bamonti-Catena F, Buccianti G, Porcella A et al. Folate measurements in patients on regular hemodialysis treatment. Am J Kidney Dis 1999; 33: Breen CP, Macdougall IC. Correction of epoetin-resistant megaloblastic anaemia following vitamin B(12) and folate administration. Nephron 1999; 83: Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron 1995; 71: Blumberg A, Zehnder C, Huber A. Folic acid supplementation rarely improves erythropoietin response. Nephron 1998; 78: Wang MC, Huang J-J, Liao LH et al. Effect of high-dose folic acid on hemodialysis patients with poor erythropoietin response. Dial Transplant 2000; 29: Received for publication: Accepted in revised form:
An Audit of Poor Response To Erythropoeitin Therapy. September 1998
1 An Audit of Poor Response To Erythropoeitin Therapy September 1998 Prepared By: Nicola Austerberry Renal Audit Facilitator Phil Kalra Consultant Nephrologist 2 1 Introduction The topic for this audit
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease
32 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease N Nand 1, S Venu 2, AR Deshmukh 2, R Mittal 2 ORIGINAL ARTICLE Abstract This study
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationROYAL WOLVERHAMPTON HOSPITALS NHS TRUST
ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationTypes of Anaemias and their Management. S. Moncrieffe, Pharm.D., MPH, Dip.Ed., RPh. PSJ CE Mandeville Hotel April 27, 2014
Types of Anaemias and their Management S. Moncrieffe, Pharm.D., MPH, Dip.Ed., RPh. PSJ CE Mandeville Hotel April 27, 2014 Objectives At the end of the presentations participants should be able to: 1. Define
More informationLife Science Journal 2013;10(4)
Short Term Low Dose Intravenous Ascorbic Acid in Functional Iron Deficiency Anemia in Hemodialysis Patients Magdy El-Sharkawy¹, Walid Bichari ¹, Mostafa Kamel ¹ and Hanaa Fathey ² ¹ Internal Medicine and
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationNUTRITIONAL CARE IN ANEMIA
االله الرحمن الرحيم بسم NUTRITIONAL CARE IN ANEMIA Nutrition Departement Faculty of Medicine University of North Sumatera Definition Deficit of circulating RBC associated with diminished oxygen-carrying
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationPrevalence and severity of anemia in pediatric hemodialysis patients, a single center study
Received:16.7.2006 Accepted: 6.12.2006 Short Communication Prevalence and severity of anemia in pediatric hemodialysis patients, a single center study Afshin Azhir*, Jafar Nasiri**, Alaleh Gheisari* Abstract
More informationRenal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail et al. BMC Nephrology (2017) 18:345 DOI 10.1186/s12882-017-0688-1 CORRESPONDENCE Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Ashraf Mikhail 1*, Christopher
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationI. Definitions. V. Evaluation A. History B. Physical Exam C. Laboratory evaluation D. Bone marrow examination E. Specialty referrals
I. Definitions II. III. Red blood cell life cycle Iron metabolism IV. Causes of anemia A. Kinetic approach 1. decreased production 2. increased destruction 3. blood loss B. Morphologic approach 1. normocytic
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationOPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationA Novel Approach for the Screening of Megaloblastic Anaemia
Feb. 2012, Volume 9, No. 2 (Serial No. 87), pp. 71 79 Journal of US-China Medical Science, ISSN 1548-6648, USA D DAVID PUBLISHING A Novel Approach for the Screening of Megaloblastic Anaemia R. Simon-Lopez
More informationNutritional anaemia. Dr J Potgieter Dept of Haematology NHLS - TAD
Nutritional anaemia Dr J Potgieter Dept of Haematology NHLS - TAD Classification of anaemia Microcytic, hypochromic MCV < 80fl MCH > 27pg Iron deficiency Anaemia of chronic disease Thalassaemia Lead poisoning
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationi. Where is the participant seen?
PFU01 method used: Phone/in-person interview 1 Enter PIP # here: Online survey 2 Enter Web # here: Initials of person completing form: Date Form Completed: / / Form Version: 03 / 01 / 18 Is the participant
More informationAppropriateness of anemia management in hemodialysis patients
Saudi Pharmaceutical Journal (2012) 20, 85 91 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com PRACTICE REPORT Appropriateness of anemia management in hemodialysis
More informationSerum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation
The Journal of International Medical Research 2011; 39: 1961 1967 Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation Y XU, XQ DING, JZ ZOU, ZH LIU, SH JIANG AND
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationClinical Practice Guideline Anaemia of Chronic Kidney Disease
Clinical Practice Guideline Anaemia of Chronic Kidney Disease Final Version: June 2017 Review Date: June 2022 Authors: Dr Ashraf Mikhail Consultant Nephrologist, Abertawe Bro Morgannwg University Health
More informationPRESERVATION OF RESIDUAL RENAL FUNCTION IN DIALYSIS PATIENTS: EFFECTS OF DIALYSIS-TECHNIQUE RELATED FACTORS
Peritoneal Dialysis International, Vol. 21, pp. 52 57 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2001 International Society for Peritoneal Dialysis PRESERVATION OF RESIDUAL
More informationIron deficiency is the most common single cause
An Efficacy, Safety and Tolerability Study of Ferrous Ascorbate and Folic Acid (Phosfomin-XT) in Iron Deficiency Anemia BB Adsul*, Qayum Mukaddam**, Prashant Khandeparkar**, Manoj Naik** Abstract Aim:
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationCONCORD INTERNAL MEDICINE CHRONIC KIDNEY DISEASE PROTOCOL. Revised May 30, 2012
CONCORD INTERNAL MEDICINE CHRONIC KIDNEY DISEASE PROTOCOL Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe III, MD Revised May 30, 2012 The information contained in this protocol
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationINFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN
INFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN, Idrizi A, Barbullushi M, Gjyzari A, Duraku A Department of Nephrology, University Hospital Center, Tirana, Albania Introduction
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTHE KENYA POLYTECHNIC UNIVERSITY COLLEGE
THE KENYA POLYTECHNIC UNIVERSITY COLLEGE SCHOOL OF HEALTH SCIENCES AND TECHNOLOGY DEPARTMENT OF BIOMEDICAL LABORATORY SCIENCES AND TECHNOLOGY DIPLOMA IN MEDICAL LABORATORY SCIENCE END OF YEAR 1 EXAMINATION
More informationThe Effect of High-Flux Hemodialysis on Dialysis-Associated Amyloidosis
Renal Failure, 1:31-34, 2005 Copyright 2005 Taylor & Francis Inc. ISSN: 0886-022X print / 1525-6049 online DOI: 10.1081/JDI-200042868 Taylor & Francis Taylor 6. Francis Croup CLINICAL STUDY The Effect
More informationINTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED
INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED Rationale for Combining Iron & Vit-D Vit D deficiency and Iron deficiency Anaemia the two most menacing disorders - are inter-related
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationHEALTHYSTART TRAINING MANUAL. Living well with Kidney Disease
HEALTHYSTART TRAINING MANUAL Living well with Kidney Disease KIDNEY DISEASE CAN AFFECT ANYONE! 1 HEALTHYSTART PROGRAMME HEALTHYSTART is a lifestyle management programme to assist you to remain healthy
More informationTopic owner: Mollie Grow MD MPH, updated June 2018
Iron deficiency Anemia UW Pediatrics Outpatient Clinical Guidelines Sources: AAP Clinical Report Diagnosis and Prevention of Iron Deficiency and Iron- Deficiency Anemia in Infants and Young Children (0
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationNUTRITIONAL ANEMIAS K Y L I E P E T E R S O N & E M I L Y S T E W A R T S A O R I S A K I T A & M A R J O R I E M I L L E R
NUTRITIONAL ANEMIAS K Y L I E P E T E R S O N & E M I L Y S T E W A R T S A O R I S A K I T A & M A R J O R I E M I L L E R ANEMIA Anemia: a deficiency in the size/number of RBC or the amount of hemoglobin
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant ( 1997) 12: 1223 1228 Original Article Nephrology Dialysis Transplantation Reduced calcium dialysate in CAPD patients: ecacy and limitations A. Armstrong1, J. Beer1, K. Noonan2
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free
More informationYing Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1.
BioMed Research International Volume 2016, Article ID 1523124, 7 pages http://dx.doi.org/10.1155/2016/1523124 Research Article Association between the Achievement of Target Range CKD-MBD Markers and Mortality
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationPROSPECTIVE RANDOMIZED CROSS-OVER LONG-TERM COMPARISON OF ONLINE HAEMODIAFILTRATION AND ULTRAPURE HIGH-FLUX HAEMODIALYSIS
26 EU RO PE AN JOUR NAL OF MED I CAL RE SEARCH January 31, 2007 Eur J Med Res (2007) 12: 26-33 I. Holzapfel Publishers 2007 PROSPECTIVE RANDOMIZED CROSS-OVER LONG-TERM COMPARISON OF ONLINE HAEMODIAFILTRATION
More informationDETECTION, INVESTIGATION AND MANAGEMENT OF ANAEMIA
From the Chief Medical Officer Dr Michael McBride HSS(MD) 22/2012 Circulation list: For Action: Chief Executives of HSC Trusts Medical Directors of HSC Trusts (for onward distribution to All Hospital Doctors)
More informationThe LaboratoryMatters
Laboratory Medicine Newsletter for clinicians, pathologists & clinical laboratory technologists. A Initiative. Complete Blood Count This issue highlights: CBC, while ubiquitous, is an excellent diagnostic
More informationPredictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran
Dialysis Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran Monir Sadat Hakemi, 1 Mehdi Golbabaei, 2 Amirahmad Nassiri, 3 Mandana
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationAnemia treatment in dialysis patients and related problem
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Anemia treatment in dialysis patients and related problem FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationHepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity
1 Hepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity Dr. Salwa Ibrahim, MD MRCP Assistant Professor of Nephrology Cairo University, Egypt Patients on hemodialysis therapy
More informationGeneral Characterisctics
Anemia General Characterisctics Definition: anemia is a decrease in red blood cells. Happens due to underproduction, increased destruction or loss of red cells. Diagnosis of anemia: Hgb < 135 (men) Hgb
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More information17 th Annual Meeting of JSHDF, Sept 3-4, 2011
17 th Annual Meeting of JSHDF, Sept 3-4, 2011 Sug Kyun Shin 1, JY Moon 2, SW Han 3, DH Yang 4, SH Lee 2, HC Park 5, JK Kim 6 and YI Jo 7 1 Nephrology, NHIC Ilsan Hospital, 2 Kyunghee University Hospital
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationOriginal Article Anemia management trends in patients on peritoneal dialysis in the past 10 years
Int J Clin Exp Med 2015;8(10):18050-18057 www.ijcem.com /ISSN:1940-5901/IJCEM0011104 Original Article Anemia management trends in patients on peritoneal dialysis in the past 10 years Huaye Liu, Yao Yao,
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationVitamin B12 treatment guideline
Vitamin B12 treatment guideline What are the signs of B12 deficiency? Haematological (in order of increasing severity) Isolated red cell macrocytosis without anaemia Macrocytic anaemia (esp if MCV >110fl)
More informationInternationally indexed journal
www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,
More informationHAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore
HAEMATOLOGICAL EVALUATION OF ANEMIA Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore Learning Objectives Laboratory tests for the evaluation of anemia
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationDr. Hasan Fahmawi, MRCP (London), FRCP(Edin) Consultant Physician ANAEMIA
Dr. Hasan Fahmawi, MRCP (London), FRCP(Edin) Consultant Physician ANAEMIA Definition Anaemia refers to a state in which haemoglobin in the blood is below the reference range appropriate for age and
More informationClinician Blood Panel Results
Page 1 of 8 Blood Panel - Markers Out of Range and Patterns (Pattern: proprietary formula using one or more Blood Markers) Blood Panel: Check for Markers that are out of Lab Range ***NOTE*** Only one supplement
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationDarbepoetin alfa (Aranesp TM )inchildren with chronic renal failure
Kidney International, Vol. 68 (2005), pp. 1759 1765 Darbepoetin alfa (Aranesp TM )inchildren with chronic renal failure DENIS F. GEARY, LAURA E. KEATING, ANNETTE VIGNEUX, DEREK STEPHENS, DIANE HÉBERT,
More informationAnemia in ESRD patients is effectively treated by the
Randomized Trial of Model Predictive Control for Improved Anemia Management Michael E. Brier,* Adam E. Gaweda, Andrew Dailey, George R. Aroff, and Alfred A. Jacobs *Department of Veterans Affairs, Louisville,
More informationUREMIC PRURITUS IN THE MAINTENANCE OF HEMODIALYSIS PATIENTS
63 UREMIC PRURITUS IN THE MAINTENANCE OF HEMODIALYSIS PATIENTS WEN-YUAN CHIU, HORNG-RONG CHANG*, ENNY HALIM, JONG-DA LIAN* Pruritus is a common symptom among patients on hemodialysis (HD). We studied 68
More informationLLL Session - Nutritional support in renal disease
ESPEN Congress Leipzig 2013 LLL Session - Nutritional support in renal disease Peritoneal dialysis D. Teta (CH) Nutrition Support in Patients undergoing Peritoneal Dialysis (PD) Congress ESPEN, Leipzig
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationCorrelation between Inflammatory Biomarkers and Red Blood Cell Life Span in Chronic Hemodialysis Patients
Original Paper Advances in CKD 2017 Published online: January 24, 2017 Biomarkers and Red Blood Cell Life Span in Chronic Hemodialysis Patients Jie Ma a, b Yanna Dou a, c Hanjie Zhang a Stephan Thijssen
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationMorphological classification of anaemia among first-time blood donors in Northwest Nigeria and the implication of empirical haematinics therapy
International Journal of Biomedical and Health Sciences 0794-4748/2011 $5.00 + 0.00 Vol. 7, No. 2, June 30, 2011 2011 African Studies on Population and Health Printed in Nigeria http://www.asopah.org IJBHS
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More information